NIRV Stock Overview
Engages in the research and development of therapeutic products to address addiction. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Nirvana Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.035 |
| 52 Week High | CA$0.08 |
| 52 Week Low | CA$0.01 |
| Beta | 0.76 |
| 1 Month Change | -30.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| NIRV | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | -0.002% |
| 1Y | n/a | -48.5% | 17.3% |
Return vs Industry: Insufficient data to determine how NIRV performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NIRV performed against the Canadian Market.
Price Volatility
| NIRV volatility | |
|---|---|
| NIRV Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: NIRV's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine NIRV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Bruce Clark | nirvanalifescience.com |
Nirvana Life Sciences Inc. engages in the research and development of therapeutic products to address addiction. The company is headquartered in Vancouver, Canada.
Nirvana Life Sciences Inc. Fundamentals Summary
| NIRV fundamental statistics | |
|---|---|
| Market cap | CA$1.69m |
| Earnings (TTM) | -CA$459.52k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs NIRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NIRV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$459.52k |
| Earnings | -CA$459.52k |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0095 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.6% |
How did NIRV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 09:37 |
| End of Day Share Price | 2025/02/10 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nirvana Life Sciences Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.